Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase

Biochemistry
Carla NecklesPeter J Tonge

Abstract

There is growing awareness of the link between drug-target residence time and in vivo drug activity, and there are increasing efforts to determine the molecular factors that control the lifetime of a drug-target complex. Rational alterations in the drug-target residence time require knowledge of both the ground and transition states on the inhibition reaction coordinate, and we have determined the structure-kinetic relationship for 22 ethyl- or hexyl-substituted diphenyl ethers that are slow-binding inhibitors of bpFabI1, the enoyl-ACP reductase FabI1 from Burkholderia pseudomallei. Analysis of enzyme inhibition using a two-dimensional kinetic map demonstrates that the ethyl and hexyl diphenyl ethers fall into two distinct clusters. Modifications to the ethyl diphenyl ether B ring result in changes to both on and off rates, where residence times of up to ∼700 min (∼11 h) are achieved by either ground state stabilization (PT444) or transition state destabilization (slower on rate) (PT404). By contrast, modifications to the hexyl diphenyl ether B ring result in residence times of 300 min (∼5 h) through changes in only ground state stabilization (PT119). Structural analysis of nine enzyme:inhibitor complexes reveals that the varia...Continue Reading

References

Jan 1, 1988·Advances in Enzymology and Related Areas of Molecular Biology·J F Morrison, C T Walsh
Aug 26, 1998·Nature·L M McMurryS B Levy
Nov 7, 1998·The Journal of Biological Chemistry·R J HeathC O Rock
Apr 10, 1999·The Journal of Biological Chemistry·R J HeathC O Rock
Apr 14, 1999·Nature·C W LevyJ B Rafferty
Jul 10, 1999·Journal of Molecular Biology·M J StewartC Kisker
Sep 7, 2001·Annual Review of Microbiology·J W Campbell, J E Cronan
Mar 19, 2002·Emerging Infectious Diseases·Lisa D RotzJames M Hughes
Dec 3, 2002·Journal of Medicinal Chemistry·Per-Olof MarkgrenU Helena Danielson
May 28, 2003·Lancet·N J White
Sep 1, 1994·Acta Crystallographica. Section D, Biological Crystallography·UNKNOWN Collaborative Computational Project, Number 4
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Apr 16, 2005·Clinical Microbiology Reviews·Allen C Cheng, Bart J Currie
Dec 22, 2005·Acta Crystallographica. Section D, Biological Crystallography·Philip Evans
Mar 17, 2006·Nature Reviews. Microbiology·W Joost WiersingaSharon J Peacock
May 2, 2006·The Journal of Biological Chemistry·Yong-Mei ZhangCharles O Rock
Jun 15, 2006·Expert Review of Anti-infective Therapy·Vanaporn Wuthiekanun, Sharon J Peacock
Aug 5, 2006·Nature Reviews. Drug Discovery·Robert A CopelandThomas D Meek
Jan 16, 2008·Accounts of Chemical Research·Hao Lu, Peter J Tonge
Apr 17, 2008·Biochemistry·Peter J Tummino, Robert A Copeland
May 7, 2008·Bioorganic & Medicinal Chemistry Letters·Christopher W am EndePeter J Tonge
Aug 1, 2007·Journal of Applied Crystallography·Airlie J McCoyRandy J Read
Sep 8, 2009·The Journal of Antimicrobial Chemotherapy·Kathleen EnglandRichard A Slayden
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Wolfgang Kabsch
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Paul D AdamsPeter H Zwart
Mar 5, 2010·The Journal of Biological Chemistry·Sylvia R LucknerCaroline Kisker
Jul 29, 2010·Current Opinion in Chemical Biology·Hao Lu, Peter J Tonge
Nov 4, 2010·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Shahila MehboobMichael E Johnson
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Nina LiuPeter J Tonge
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Garib N MurshudovAlexei A Vagin
Aug 10, 2011·Antimicrobial Agents and Chemotherapy·S EscaichC Soulama-Mouze
Aug 25, 2011·Current Opinion in Microbiology·Joshua B Parsons, Charles O Rock
Sep 3, 2011·Future Medicinal Chemistry·Robert A Copeland
Apr 17, 2012·Acta Crystallographica. Section D, Biological Crystallography·Pavel V AfoninePaul D Adams
Apr 20, 2012·Journal of Synchrotron Radiation·Uwe MuellerManfred S Weiss
Apr 20, 2012·Journal of Synchrotron Radiation·Daniele de SanctisChristoph Mueller-Dieckmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Protein Structures

Bacterial protein structures can expedite the development of novel antibiotics. Here is the latest research on bacterial proteins and the resolution of their structures.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Protein Structures (ASM)

Bacterial protein structures can expedite the development of novel antibiotics. Here is the latest research on bacterial proteins and the resolution of their structures.